levocetirizine dihydrochloride

levocetirizine dihydrochloride


Pharmacologic class: Histamine1 (H1)-receptor antagonist

Therapeutic class: Antihistamine

Pregnancy risk category B


Exerts principal antihistaminic effects via selective inhibition of H1 receptors


Oral solution: 2.5 mg/5 ml (0.5 mg/ml)

Tablets: 5 mg

Indications and dosages

Symptoms of allergic rhinitis (seasonal and perennial); uncomplicated skin manifestations of chronic idiopathic urticaria

Adults and children ages 12 and older: 5 mg P.O. daily in evening

Children ages 6 to 11: 2.5 mg P.O. daily in evening; don't exceed recommended dosage.

Dosage adjustment

• Renal impairment.
• Hepatic impairment


• Hypersensitivity to drug, its components, or cetirizine
• End-stage renal disease
• Hemodialysis
• Renal impairment (children ages 6 to 11)


Use cautiously in:
• renal impairment
• pregnant patients
• elderly patients
• breastfeeding patients (use not recommended)
• children younger than age 6 (safety and efficacy not established).


• Give with or without food.

Adverse reactions

CNS: somnolence, fatigue, asthenia

EENT: epistaxis (children), nasopharyngitis, pharyngitis

GI: dry mouth

Respiratory: cough (children)

Other: pyrexia (children)


Drug-drug.Ritonavir: increased levocetirizine blood level and half-life, decreased clearance

Drug-behaviors.Alcohol use: increased risk of impaired CNS function

Patient monitoring

• Stay alert for excessive CNS depression.
• Closely monitor renal function tests in patients with renal impairment.

Patient teaching

• Tell patient drug can be taken with or without food.
• Instruct patient to avoid alcohol and other depressants, such as sleeping pills, unless prescriber approves.
• Caution patient to avoid hazardous activities until drug's effects on concentration and alertness are known.
• Advise female patient to notify prescriber if she is pregnant or intends to become pregnant.
• Tell breastfeeding patient to discontinue breastfeeding during therapy.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

Mentioned in ?
References in periodicals archive ?
FDA) for Levocetirizine Dihydrochloride 5 mg tablets, the generic version of UCB Inc.
Glenmark's levocetirizine dihydrochloride tablets are currently available and shipping will commence immediately from the Company's New Jersey facility.
Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: the results of research, development and clinical trials; the timing and success of submission, acceptance, and approval of regulatory filings; the time and resources UCB devotes to the development and commercialization of levocetirizine dihydrochloride and the scope of UCB's patents and the patents of others.